Efficacies of Entecavir against Lamivudine-Resistant Hepatitis B Virus Replication and Recombinant Polymerases In Vitro
Entecavir (ETV) is a potent and selective inhibitor of hepatitis B virus (HBV) replication in vitro and in vivo that is currently in clinical trials for the treatment of chronic HBV infections. A major limitation of the current HBV antiviral therapy, lamivudine (3TC), is the emergence of drug-resist...
Gespeichert in:
| Veröffentlicht in: | Antimicrob Agents Chemother |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
American Society for Microbiology (ASM)
2002
|
| Schlagworte: | |
| Online-Zugang: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC127388/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12121928/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.46.8.2525-2532.2002 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|
